Sheryl Dizon - Associate Director, Reimbursement and Patient Access - Puma Biotechnology, Inc. | LinkedIn
Neratinib + fulvestrant + trastuzumab for hormone-receptor positive, HER2-negative, HER2-mutant metastatic breast cancer: outcom
![FDA Approves Dose Escalation Label Update for Puma Biotechnology's NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer | Business Wire FDA Approves Dose Escalation Label Update for Puma Biotechnology's NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer | Business Wire](https://mms.businesswire.com/media/20210701005217/en/889083/23/4357884cpuma_logo_JPEG.jpg)
FDA Approves Dose Escalation Label Update for Puma Biotechnology's NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer | Business Wire
![Senior Manager, Quality Assurance Operations Job in South San Francisco, CA - Puma Biotechnology, Inc | pumabiotechnology.jobs.net Senior Manager, Quality Assurance Operations Job in South San Francisco, CA - Puma Biotechnology, Inc | pumabiotechnology.jobs.net](https://secure.icbdr.com/MediaManagement/GS/I2P6NR63V7ZFCCN7VGS.jpg)
Senior Manager, Quality Assurance Operations Job in South San Francisco, CA - Puma Biotechnology, Inc | pumabiotechnology.jobs.net
![Komen SF Bay Area on Twitter: "Thank you to Puma Biotechnology for being a Diamond level sponsor of our San Francisco Race for the Cure. Stop by Puma Biotechnology's booth on Race Komen SF Bay Area on Twitter: "Thank you to Puma Biotechnology for being a Diamond level sponsor of our San Francisco Race for the Cure. Stop by Puma Biotechnology's booth on Race](https://pbs.twimg.com/media/DgesuDRU8AAxF8L.jpg)